JPWO2023036473A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023036473A5 JPWO2023036473A5 JP2024515026A JP2024515026A JPWO2023036473A5 JP WO2023036473 A5 JPWO2023036473 A5 JP WO2023036473A5 JP 2024515026 A JP2024515026 A JP 2024515026A JP 2024515026 A JP2024515026 A JP 2024515026A JP WO2023036473 A5 JPWO2023036473 A5 JP WO2023036473A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- unsubstituted
- pharmaceutical composition
- substituted
- dmt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- ZSTKHSQDNIGFLM-UHFFFAOYSA-N 5-methoxy-N,N-dimethyltryptamine Chemical compound COC1=CC=C2NC=C(CCN(C)C)C2=C1 ZSTKHSQDNIGFLM-UHFFFAOYSA-N 0.000 claims 12
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 11
- DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical compound C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 claims 8
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 8
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 8
- 208000020016 psychiatric disease Diseases 0.000 claims 8
- 239000000018 receptor agonist Substances 0.000 claims 8
- 229940044601 receptor agonist Drugs 0.000 claims 7
- 208000015114 central nervous system disease Diseases 0.000 claims 6
- 229910052805 deuterium Inorganic materials 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 208000024714 major depressive disease Diseases 0.000 claims 6
- 239000001272 nitrous oxide Substances 0.000 claims 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 4
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 4
- 208000029364 generalized anxiety disease Diseases 0.000 claims 4
- -1 2-(5-methoxy-1H-indol-3-yl)-N,N-bis(methyl-d3)ethan-1-amine-1,1,2,2-d4 Chemical compound 0.000 claims 3
- 208000007848 Alcoholism Diseases 0.000 claims 3
- DMULVCHRPCFFGV-TXNVYZHYSA-N [2H]C([2H])([2H])N(C([2H])([2H])[2H])C([2H])([2H])C([2H])([2H])C1=CNC2=CC=CC=C12 Chemical compound [2H]C([2H])([2H])N(C([2H])([2H])[2H])C([2H])([2H])C([2H])([2H])C1=CNC2=CC=CC=C12 DMULVCHRPCFFGV-TXNVYZHYSA-N 0.000 claims 3
- 208000025746 alcohol use disease Diseases 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 3
- 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 claims 2
- 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 claims 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 206010065604 Suicidal behaviour Diseases 0.000 claims 2
- 206010042458 Suicidal ideation Diseases 0.000 claims 2
- 208000018912 cluster headache syndrome Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 229960003299 ketamine Drugs 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 claims 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000027521 Childhood-Onset Fluency disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 208000001613 Gambling Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 206010026864 Masochism Diseases 0.000 claims 1
- 208000027626 Neurocognitive disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000026251 Opioid-Related disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- 208000014679 binge eating disease Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 150000001975 deuterium Chemical group 0.000 claims 1
- 229960001985 dextromethorphan Drugs 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 208000003481 exhibitionism Diseases 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 230000003400 hallucinatory effect Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000003995 melancholia Diseases 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229960001730 nitrous oxide Drugs 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 201000005814 sexual masochism Diseases 0.000 claims 1
- 208000027599 sexual masochism disease Diseases 0.000 claims 1
- 208000027596 sexual sadism disease Diseases 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163241891P | 2021-09-08 | 2021-09-08 | |
| US63/241,891 | 2021-09-08 | ||
| PCT/EP2022/058574 WO2023036473A1 (en) | 2021-09-08 | 2022-03-31 | Combination drug therapies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024533291A JP2024533291A (ja) | 2024-09-12 |
| JPWO2023036473A5 true JPWO2023036473A5 (https=) | 2025-03-25 |
| JP2024533291A5 JP2024533291A5 (https=) | 2025-03-25 |
Family
ID=81325378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024515026A Pending JP2024533291A (ja) | 2021-09-08 | 2022-03-31 | 併用薬物療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240366655A1 (https=) |
| EP (1) | EP4398871A1 (https=) |
| JP (1) | JP2024533291A (https=) |
| KR (1) | KR20240052775A (https=) |
| AU (1) | AU2022342266B2 (https=) |
| CA (1) | CA3231021A1 (https=) |
| WO (1) | WO2023036473A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021268204A1 (en) | 2020-05-08 | 2022-12-08 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US12122741B2 (en) | 2020-08-18 | 2024-10-22 | Cybin Irl Limited | Therapeutic phenethylamine compositions and methods of use |
| IL308816A (en) | 2021-05-25 | 2024-01-01 | Atai Therapeutics Inc | New n,n-dimethyltryptamine salts and crystalline salt forms |
| MX2023014620A (es) | 2021-06-09 | 2024-01-30 | Atai Therapeutics Inc | Nuevos profarmacos y conjugados de dimetiltriptamina. |
| JP2024545787A (ja) | 2021-12-30 | 2024-12-11 | アタイ セラピューティクス， インコーポレイテッド | 一酸化窒素送達剤としてのジメチルトリプタミン類似体 |
| GB202214721D0 (en) * | 2022-10-06 | 2022-11-23 | Rewire Therapeutics Ltd | A treatment for mental disorders |
| EP4704826A1 (en) * | 2023-04-28 | 2026-03-11 | Yale University | Compositions and methods for treating post-traumatic stress disorder |
| US12303503B1 (en) | 2023-11-16 | 2025-05-20 | Biobina Llc | Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain |
| WO2025123137A1 (en) * | 2023-12-15 | 2025-06-19 | 10763942 Canada Inc. (Dba. Purminds Neuropharma) | Heterocyclic compounds and methods of preparation thereof |
| WO2025170990A1 (en) * | 2024-02-06 | 2025-08-14 | Atai Therapeutics, Inc. | Controlled transmucosal release of dmt in combination with a monoamine oxidase inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| US7267121B2 (en) | 2004-04-20 | 2007-09-11 | Aerogen, Inc. | Aerosol delivery apparatus and method for pressure-assisted breathing systems |
| EP4219498A1 (en) * | 2019-03-07 | 2023-08-02 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations |
| KR20220009954A (ko) * | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| WO2021003467A1 (en) * | 2019-07-04 | 2021-01-07 | Sw Holdings, Inc. | Metered dosing compositions and methods of use of psychedelic compounds |
| RU199823U1 (ru) | 2020-06-10 | 2020-09-21 | Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий | Устройство для лечения бронхолегочных заболеваний |
-
2022
- 2022-03-31 WO PCT/EP2022/058574 patent/WO2023036473A1/en not_active Ceased
- 2022-03-31 AU AU2022342266A patent/AU2022342266B2/en active Active
- 2022-03-31 CA CA3231021A patent/CA3231021A1/en active Pending
- 2022-03-31 US US18/688,125 patent/US20240366655A1/en active Pending
- 2022-03-31 KR KR1020247008355A patent/KR20240052775A/ko active Pending
- 2022-03-31 JP JP2024515026A patent/JP2024533291A/ja active Pending
- 2022-03-31 EP EP22716971.1A patent/EP4398871A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2023036473A5 (https=) | ||
| IL297492A (en) | Deuterated tryptamine derivatives and methods of use | |
| CN100430394C (zh) | N-[杂芳基(哌啶-2-基)甲基]苯甲酰胺衍生物及其制备方法和它们的治疗应用 | |
| JP4754494B2 (ja) | Ｎ−［フェニル（アルキルピペリジン−２−イル）メチル］ベンズアミド誘導体、この調製方法およびこの治療法における使用 | |
| JPWO2021234608A5 (https=) | ||
| CN100575334C (zh) | 取代的2-二烷基氨基烷基联苯衍生物 | |
| JP2021519267A5 (https=) | ||
| JPH06508354A (ja) | トリプタミン類似体、その合成法およびその５−ｈｔ↓１様または５−ｈｔ↓２受容体作用物質としての使用 | |
| JP2005527593A (ja) | Ｎ−［フェニル（ピペリジン−２−イル）メチル］ベンズアミド誘導体類、それらの製造方法および治療におけるそれらの使用 | |
| KR20110015449A (ko) | 아르포르모테롤의 합성방법 | |
| CN1477961A (zh) | 哌嗪衍生物、它们的制备方法及其治疗中枢神经系统(cns)疾病的应用 | |
| JPWO2022069690A5 (https=) | ||
| CN1805956A (zh) | 苯并咪唑衍生物、含有它们的组合物、它们的制备以及它们的用途 | |
| JPWO2023078604A5 (https=) | ||
| Nichols et al. | Synthesis and serotonin receptor affinities of a series of enantiomers of. alpha.-methyltryptamines: evidence for the binding conformation of tryptamines at serotonin 5-HT1B receptors | |
| AU2935300A (en) | New pharmaceutical combinations for nos inhibitors | |
| RU2007106970A (ru) | Новые хромен-2-оновые производные и их применение в качестве ингибиторов обратного захвата моноаминовых нейромедиаторов | |
| JPWO2022038170A5 (https=) | ||
| JP3984281B2 (ja) | ３−アザビシクロ〔３，２，１〕オクタン誘導体 | |
| CN1307574A (zh) | 作为5－羟色胺能药物的吲哚基衍生物 | |
| JPWO2022038171A5 (https=) | ||
| TW200819455A (en) | Pyrrolizine, indolizine and quinolizine derivatives, their preparation and their therapeutic application | |
| JPWO2023186963A5 (https=) | ||
| JP2006517568A5 (https=) | ||
| JP2006517567A5 (https=) |